Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Debt (2019 - 2025)

Tg Therapeutics has reported Total Debt over the past 7 years, most recently at $245.6 million for Q4 2025.

  • Quarterly results put Total Debt at $245.6 million for Q4 2025, changed 0.5% from a year ago — trailing twelve months through Dec 2025 was $245.6 million (changed 0.5% YoY), and the annual figure for FY2025 was $245.6 million, changed 0.5%.
  • Total Debt for Q4 2025 was $245.6 million at Tg Therapeutics, roughly flat from $245.3 million in the prior quarter.
  • Over the last five years, Total Debt for TGTX hit a ceiling of $245.6 million in Q4 2025 and a floor of $16.0 million in Q3 2021.
  • Median Total Debt over the past 5 years was $98.3 million (2023), compared with a mean of $124.1 million.
  • Biggest five-year swings in Total Debt: tumbled 46.07% in 2021 and later surged 344.62% in 2022.
  • Tg Therapeutics' Total Debt stood at $67.8 million in 2021, then increased by 4.98% to $71.1 million in 2022, then surged by 40.74% to $100.1 million in 2023, then surged by 144.14% to $244.4 million in 2024, then grew by 0.5% to $245.6 million in 2025.
  • The last three reported values for Total Debt were $245.6 million (Q4 2025), $245.3 million (Q3 2025), and $245.0 million (Q2 2025) per Business Quant data.